Title :

Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study

Author(s) :

Gronnier, Caroline [Auteur]
Hôpital Haut-Lévêque [CHU Bordeaux]
Mariette, Christophe [Auteur]
Hôpital Claude Huriez [Lille]
Lepage, Come [Auteur]
Monterymard, Carole [Auteur]
Lipides - Nutrition - Cancer [Dijon - U1231] [LNC]
Jary, Marine [Auteur]
CHU Clermont-Ferrand
Ferru, Aurélie [Auteur]
Baconnier, Mathieu [Auteur]
Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois]
Adhoute, Xavier [Auteur]
Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille]
Tavan, David [Auteur]
Perrier, Hervé [Auteur]
Clinique de l'Infirmerie Protestante de Lyon [CIPL]
Guerin-Meyer, Véronique [Auteur]
Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO]
Lecaille, Cédric [Auteur]
Polyclinique Bordeaux Nord Aquitaine [PBNA]
Bonichon-Lamichhane, Nathalie [Auteur]
Clinique Tivoli Ducos [Bordeaux]
Pillon, Didier [Auteur]
Cojocarasu, Oana [Auteur]
Egreteau, Joëlle [Auteur]
Groupe Hospitalier Bretagne Sud [GHBS]
D’journo, Xavier Benoit [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Dahan, Laétitia [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Locher, Christophe [Auteur]
Centre Hospitalier de Meaux
Texereau, Patrick [Auteur]
CHU Mont de Marsan
Collet, Denis [Auteur]
Michel, Pierre [Auteur]
Ben Abdelghani, Meher [Auteur]
Guimbaud, Rosine [Auteur]
Muller, Marie [Auteur]
Bouché, Olivier [Auteur]
Piessen, Guillaume [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]

Journal title :

Cancers

Pages :

2188

Publisher :

MDPI

Publication date :

2023-04-06

ISSN :

2072-6694

English keyword(s) :

esogastric adenocarcinoma
neoadjuvant chemotherapy
cetuximab
surgery
efficacy
safety
EGFR-1

HAL domain(s) :

Sciences du Vivant [q-bio]/Cancer

English abstract : [en]

Purpose: While perioperative chemotherapy provides a survival benefit over surgery alone in gastric and gastroesophageal junction (G/GEJ) adenocarcinomas, the results need to be improved. This study aimed to evaluate the ...
Show more >Purpose: While perioperative chemotherapy provides a survival benefit over surgery alone in gastric and gastroesophageal junction (G/GEJ) adenocarcinomas, the results need to be improved. This study aimed to evaluate the efficacy and safety of perioperative cetuximab combined with 5-fluorouracil and cisplatin. Patients and Methods: Patients received six cycles of cetuximab, cisplatin, and simplified LV5FU2 before and after surgery. The primary objective was a combined evaluation of the tumor objective response (TOR), assessed by computed tomography, and the absence of major toxicities resulting in discontinuation of neoadjuvant chemotherapy (NCT) (45% and 90%, respectively). Results: From 2011 to 2013, 65 patients were enrolled. From 64 patients evaluable for the primary endpoint, 19 (29.7%) had a morphological TOR and 61 (95.3%) did not stop NCT prematurely due to major toxicity. Sixty patients (92.3%) underwent resection. Sixteen patients (/56 available, 28.5%) had histological responses (Mandard tumor regression grade ≤3). After a median follow-up of 44.5 months, median disease-free and overall survival were 24.4 [95% CI: 16.4-39.4] and 40.3 months [95% CI: 27.5-NA], respectively. Conclusion: Adding cetuximab to the NCT regimen in operable G/GEJ adenocarcinomas is safe, but did not show enough efficacy in the present study to meet the primary endpoint (NCT01360086).Show less >

Language :

Anglais

Popular science :

Non

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277

Source :

Harvested from HAL